Biomarkers to predict functional outcome of beta cell therapy trials in type 1 diabetes

Medicine & Life Sciences

• Cell- and Tissue-Based Therapy 100%
• Autoantibodies 97%
• Type 1 Diabetes Mellitus 94%
• Biomarkers 68%
• Zinc Transporter 8 61%
• HLA-DQ8 antigen 57%
• Insulin 47%
• Immunogenetics 46%
• Islets of Langerhans Transplantation 45%
• HLA-A Antigens 43%
• C-Peptide 40%
• Cell Transplantation 37%
• Precision Medicine 37%
• Insulin-Secreting Cells 37%
• Genetic Markers 36%
• Genetic Predisposition to Disease 35%
• Islets of Langerhans 35%
• Hyperglycemia 32%
• Allografts 30%
• Autoimmune Diseases 30%
• Placebos 24%
• Antigens 22%
• T-Lymphocytes 21%
• Databases 21%
• Antibodies 19%
• Therapeutics 11%